Replies to post #401753 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

No, he can’t say that, because publication route was decided before unblinding. Listen closely BSB, even Ex thinks they succeeded on four endpoints — including the primary endpoint.

There are six endpoints in all.

Most on this message board believe DCVax-l either met five of six, or six of six endpoints.

What he did tell femike, was that they are working toward possible approval, and that they can’t rush the Journal, but the lack of a current public TLD announcement wasn’t slowing any efforts to try and obtain approval.

[marzan]

Nowhere I sense like what you see BSB in this conversation that FM had with DI, but it is still good, imo. I think you inferred from the CVM part. But I read DI's mind like pub is needed when they went out to compare with SOCs. All I see is It is GBM; not head & neck cancer. Meeting just 2 endpoints, the pps will still go thru the roof, imo.